株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

化学療法誘発性悪心・嘔吐(CINV) - パイプライン製品の分析

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 245963
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
化学療法誘発性悪心・嘔吐(CINV) - パイプライン製品の分析 Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017
出版日: 2017年03月08日 ページ情報: 英文 88 Pages
概要

化学療法誘発性悪心・嘔吐(CINV)は、化学療法によって引き起こされる心拍数の上昇、発汗、めまい、唾液の増加といった悪心嘔吐の症状であり、その発病要因は年齢、薬剤、投与、投与スケジュールおよび投与経路などとされています。

当レポートでは、化学療法誘発性悪心・嘔吐(CINV)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

化学療法誘発性悪心・嘔吐(CINV)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

治療薬の開発に従事している企業

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9014IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 4, 2, 1, 9, 2 and 1 respectively.

Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chemotherapy Induced Nausea and Vomiting - Overview
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
    • Acacia Pharma Ltd
    • Aphios Corp
    • Astellas Pharma Inc
    • Camurus AB
    • Daewoong Pharmaceutical Co Ltd
    • Heron Therapeutics Inc
    • INSYS Therapeutics Inc
    • Kyowa Hakko Kirin Co Ltd
    • MannKind Corp
    • Medlab Clinical Ltd
    • Nemus Bioscience Inc
    • RedHill Biopharma Ltd
    • Serina Therapeutics Inc
    • SoluBest Ltd
    • Suda Ltd
    • Tesaro Inc
    • Therapix Biosciences Ltd
  • Chemotherapy Induced Nausea and Vomiting - Drug Profiles
    • (netupitant + palonosetron hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (palonosetron hydrochloride + Pro-netupitant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • APD-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aprepitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cannabis CINV - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FK-886 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosnetupitant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • granisetron hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1504 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LPI-1505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-2111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palmidrol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • palonosetron hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rolapitant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-232 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Zindol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products
  • Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
    • Featured News & Press Releases
      • Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY
      • Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)
      • Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
      • Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
      • Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore
      • Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting
      • Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
      • Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
      • May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
      • Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting
      • Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
      • Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
      • Feb 01, 2016: Biologics Announces New Oncology Partnership
      • Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top